Kezar Life Sciences, Inc.

Retooling a company to focus on a single asset is a high-risk strategy, and one that is generally taken when few other choices present themselves. Having taken this step last year, Kezar Life Science

A great deal is riding on the outcome of the Phase IIb study of Kezar Life Sciences, Inc. ’s zetomipzomib (KZR-616) in lupus nephritis, and the company is throwing the few resources it has at complet

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Hepalys Partners With Inventiva In

Kezar Life Sciences, Inc. ’s lead candidate, zetomipzomib, has produced some encouraging topline results in a Phase II trial in lupus nephritis, making up for an earlier failure for the product in ano